Abstract

MORCILLO MUNOZ, Andrés Felipe; ACOSTA FAJARDO, Hernán Andrés; ARIZA VARON, Michael Andrés  and  RAMOS ROMERO, Marta. Progressive multifocal leukoencephalopathy. Acta Neurol Colomb. [online]. 2021, vol.37, n.1, suppl.1, pp.47-54.  Epub May 21, 2021. ISSN 0120-8748.  https://doi.org/10.22379/24224022324.

The progressive multifocal leukoencephalopathy is a demyelinating disease secondary to infection to John Cunningham Virus, it has a low incidence despite a high seroprevalence in the general population. The principal risk factor for its development is an immunosuppression, including Human Immunodeficiency Virus infection, hematologic neoplasms, chronic inflammatory diseases and systemic immunosuppressive drugs. After the primary infection, the virus stays in a latent state, acquiring a neuroinvasive capacity following a set of mutations in its genome. After infecting oligodendrocytes it takes them to destruction with the consequent demyelinating process whilst its fight to the host's cellular immune system. The diagnosis is based on a set of clinical findings secondary to encephalic compromise, classically supratentorial, in addition to a demonstration of viral genome or antibodies in serum or cerebrospinal fluid and the presence of diagnostic images and histopathologic findings on the cerebral white matter. Its treatment is based on the enhancement of the disturbed immune function, with the exception of immune reconstitution state where other strategies are applied. In this paper we will review the more relevant basic and clinical aspects of this disease.

Keywords : leukoencephalopathy, progressive multifocal; HIV (MeSH).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )